Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Comprehensive Comparison of Early Relapse and End-Stage Relapsed Refractory Multiple Myeloma

Alexandra M Poos, PhD, Nicola Giesen, MD, Calogerina Catalano, PhD, Nagarajan Paramasivam, PhD, Daniel Huebschmann, MDPhD, Lukas John, Anja Baumann, Jason Hochhaus, Carsten Mueller-Tidow, MD, Sandra Sauer, MD, Stefanie Huhn, PhD, Matthias Schlesner, PhD, Benedikt Brors, PhD, Hartmut Goldschmidt, MD, Marc S. Raab, MD, Niels Weinhold, PhD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-141611

Published: 2020

Journal Articles

Impact of Novel Therapies on CD4-T-Cell-Numbers and Infectious Complications in Patients with Relapsed/Refractory Multiple Myeloma

Lukas John, Kaya Miah, Axel Benner, Elias K Mai, MD, Katharina Kriegsmann, MD, Michael Hundemer, MD, Carsten Mueller-Tidow, MD, Karin Jordan, MD, Hartmut Goldschmidt, MD, Marc S. Raab, MD, Nicola Giesen, MD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-136686

Published: 2020

Journal Articles

Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial

Marc S. Raab, MD, Nicola Giesen, MD, Christof Scheid, MD, Britta Besemer, Kaya Miah, Axel Benner, Ivana Metzler, MD, Cyrus Khandanpour, PD, MD, Andrea Seidel-Glaetzer, Karolin Trautmann-Grill, MD, Gunhild Mechtersheimer, Benjamin Goeppert, Albrecht Stenzinger, Hartmut Goldschmidt, MD, Katja Weisel, MD, Manik Chatterjee

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-142600

Published: 2020

Journal Articles

Dissecting Heterogeneity of Tumor Cells and Their Microenvironment in Refractory Multiple Myeloma

Stephan M Tirier, PhD, Jan-Philipp Mallm, PhD, Nicola Casiraghi, PhD, Hana Susak, PhD, Nicola Giesen, MD, Alexandra M Poos, PhD, Katharina Bauer, Anja Baumann, Lukas John, MD, Jing Xu, PhD, Lara Klett, MSc, Carsten Müller-Tidow, MD, Benedikt Brors, PhD, Hartmut Goldschmidt, MD, Niels Weinhold, PhD, Oliver Stegle, PhD, Karsten Rippe, PhD, Marc S. Raab, MD

Blood (2019) 134 (Supplement_1): 571.

https://doi.org/10.1182/blood-2019-128625

Published: 2019

Journal Articles

A Comprehensive Analysis of Single-Cell Chromatin Accessibility and Gene Expression Identifies Intra-Tumor Heterogeneity and Molecular Treatment Responses in Relapsed/Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 575.

https://doi.org/10.1182/blood-2019-130051

Published: 2019

Journal Articles

Mechanisms of Proteasome Inhibitor Resistance Selected By Clonal Evolution in Multiple Myeloma

Larissa Haertle, PhD, Santiago Barrio, PhD, Michal Simicek, PhD, Umair Munawar, MSc, Ricardo Sanchez, PhD MD, Max Bittrich, MD, Matteo DaVia, MD, Cornelia Vogt, MSc, Nicola Giesen, MD, Andoni Garitano-Trojaola, PhD, Silvia Nerreter, Thorsten Stuehmer, PhD, Marc S. Raab, MD, Joaquin Martinez Lopez, MD PhD, Roman Hajek, MD, Hermann Einsele, MD, Leo Rasche, MD, Thomas Haaf, MD, Martin Kortüm, MD

Blood (2019) 134 (Supplement_1): 4349.

https://doi.org/10.1182/blood-2019-130847

Published: 2019

Journal Articles

Biallelic Inactivation of Multiple Tumor Suppressors Is Associated with Early Relapse after Stem Cell Transplant in Newly Diagnosed Myeloma

Niels Weinhold, PhD, Jing Xu, PhD, Martina Fröhlich, PhD, Alexandra M Poos, PhD, Lukas John, MD, Carsten Müller-Tidow, MD, Sandra Sauer, MD, Stefanie Huhn, PhD, Dirk Hose, MD, Anja Seckinger, Kari Hemminki, MD PhD, Benedikt Brors, PhD, Hartmut Goldschmidt, MD, Nicola Giesen, MD, Marc S Raab, MD PhD

Blood (2019) 134 (Supplement_1): 1783.

https://doi.org/10.1182/blood-2019-131195

Published: 2019

NARROW

Comprehensive Comparison of Early Relapse and End-Stage Relapsed Refractory Multiple Myeloma

Impact of Novel Therapies on CD4-T-Cell-Numbers and Infectious Complications in Patients with Relapsed/Refractory Multiple Myeloma

Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial

Dissecting Heterogeneity of Tumor Cells and Their Microenvironment in Refractory Multiple Myeloma

A Comprehensive Analysis of Single-Cell Chromatin Accessibility and Gene Expression Identifies Intra-Tumor Heterogeneity and Molecular Treatment Responses in Relapsed/Refractory Multiple Myeloma

Mechanisms of Proteasome Inhibitor Resistance Selected By Clonal Evolution in Multiple Myeloma

Biallelic Inactivation of Multiple Tumor Suppressors Is Associated with Early Relapse after Stem Cell Transplant in Newly Diagnosed Myeloma

Email alerts

ASH Publications

American Society of Hematology

Comprehensive Comparison of Early Relapse and End-Stage Relapsed Refractory Multiple Myeloma

Impact of Novel Therapies on CD4-T-Cell-Numbers and Infectious Complications in Patients with Relapsed/Refractory Multiple Myeloma

Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial

Dissecting Heterogeneity of Tumor Cells and Their Microenvironment in Refractory Multiple Myeloma

A Comprehensive Analysis of Single-Cell Chromatin Accessibility and Gene Expression Identifies Intra-Tumor Heterogeneity and Molecular Treatment Responses in Relapsed/Refractory Multiple Myeloma

Mechanisms of Proteasome Inhibitor Resistance Selected By Clonal Evolution in Multiple Myeloma

Biallelic Inactivation of Multiple Tumor Suppressors Is Associated with Early Relapse after Stem Cell Transplant in Newly Diagnosed Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only